Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Mol Cancer Res. 2021 Mar 26;19(7):1196–1207. doi: 10.1158/1541-7786.MCR-20-0413

Figure 6: Patients with invasive breast cancer have decreased emerin expression.

Figure 6:

(A) Western blot analysis of protein lysates from a patient without breast cancer (control; CP565563) or from breast cancer patients. (B) Quantitation of protein lysates. Bands were normalized to actin and a patient without breast cancer (n=3). Error bars represent standard deviation. (C) qPCR analysis of matched RNA samples from one normal control patient sample and ten breast cancer patients. Samples were normalized to GAPDH and control patient sample without breast cancer. Error bars represent standard deviation. (D) Summary panel of patient tumor information.